Saturday, 31 October 2026European Markets

CROSSWOOD Stock Is 28% Up In The Last 21 Sessions

Loading stream...

as the world of stock market undergoes various fluctuations, one of the most distinct rises belongs to crosswood (cros.pa) stocks on the cac 40. these stocks have shown an impressive surge of 28.14% over just 21 sessions – increasing from eur8.35 to eur10.70! significantly, this positive swing was observed after five back-to-back sessions of declines, marking a major turn in their trajectory.

crosswood vs cac 40 index

the growth of crosswood shares brought forth an interesting contrast when compared with the movements of the cac 40 index. this index only recorded a modest gain of 0.07% at eur7,265.70 on friday, after being on a three-day decline.

crosswood's room for recovery

despite its recent show of strength, crosswood still stands 38.86% below its 52-week high that was at eur17.50, indicating there's still a significant margin for recovery.

about crosswood sa

crosswood sa, originally known as desquenne et giral from france, takes pride in an expansive property portfolio that covers shops, offices, and housing units. the operations are conducted through their subsidiary, compagnie financiere de broceliande.

earnings per share and potential profitability

the company's trailing 12-month earnings per share (eps) was reported to be eur0.57. this value is derived from the earnings for the trailing 12-month period that ended on 31 october 2013. the eps graph is a significant parameter in shares as it suggests the amount of a company's profit is being allocated to each unit of its common stocks; the higher figures usually point toward more profitability for the organization.

analysis of crosswood's price earnings ratio

a closer look at the price earnings ratio of crosswood stock discloses a pe ratio of 18.77. this ratio indicates that the investors are ready to pay eur18.77 for every euro earned each year - even after recent losses. this calculation suggests that the market participants hold high expectations for this stock, despite the recent downturn.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com